Calixa Therapeutics

Calixa Therapeutics was a privately held, San Diego-based biopharmaceutical company focused on developing antibiotics to treat serious infections caused by multi-drug-resistant Gram-negative bacterial pathogens. Its lead compound, CXA-201 (later ceftolozane/tazobactam), was an intravenous therapy for serious hospital-acquired Gram-negative infections. Calixa was acquired by Cubist Pharmaceuticals in December 2009 for approximately $92.5 million (plus up to $310 million in milestone payments) and no longer operates as an independent company. It has no public developer or API surface. This profile exists in the API Evangelist network as a portfolio-lead stub associated with canaan-partners; there are no API artifacts to enrich because it is a defunct pharmaceutical company, not an API provider.

Calixa Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Antibiotics, and Anti-Infectives.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyPharmaceuticalsBiotechnologyAntibioticsAnti-InfectivesDrug DevelopmentLife SciencesHealthcareAcquired

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/calixa-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: calixa-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/calixa-therapeutics.png
name: Calixa Therapeutics
description: Calixa Therapeutics was a privately held, San Diego-based biopharmaceutical company focused on developing antibiotics
  to treat serious infections caused by multi-drug-resistant Gram-negative bacterial pathogens. Its lead compound, CXA-201
  (later ceftolozane/tazobactam), was an intravenous therapy for serious hospital-acquired Gram-negative infections. Calixa
  was acquired by Cubist Pharmaceuticals in December 2009 for approximately $92.5 million (plus up to $310 million in milestone
  payments) and no longer operates as an independent company. It has no public developer or API surface. This profile exists
  in the API Evangelist network as a portfolio-lead stub associated with canaan-partners; there are no API artifacts to enrich
  because it is a defunct pharmaceutical company, not an API provider.
url: https://raw.githubusercontent.com/api-evangelist/calixa-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-status-note: Acquired by Cubist Pharmaceuticals in December 2009; not an independent operating company and has no public
  API surface.
x-acquired-by: cubist-pharmaceuticals
x-acquired-date: '2009-12-16'
x-industry: pharmaceuticals
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Antibiotics
- Anti-Infectives
- Drug Development
- Life Sciences
- Healthcare
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence